RedHill Biopharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
RDHL Nasdaq 2830 www.redhillbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RedHill Biopharma Ltd.

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma - Oct 19th, 2026 6:00 am
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet - Oct 1st, 2026 1:12 pm
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results - Sep 30th, 2026 2:05 pm
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties? - Sep 10th, 2026 10:06 am
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® - Sep 1st, 2026 5:00 am
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq® - Sep 1st, 2026 5:00 am
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight - Aug 31st, 2026 11:00 am
Redhill Biopharma Stock Doubles In One Session — Here's Why - Aug 31st, 2026 8:06 am
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities - Aug 31st, 2026 5:00 am
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight - Jul 30th, 2026 8:31 am
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development - Jul 28th, 2026 5:00 am
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement - Jun 22nd, 2026 2:10 pm
RedHill Biopharma Announces Up To $19.4 Million Private Placement - Jun 18th, 2026 6:00 am
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation - Jun 9th, 2026 5:00 am
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo - Jun 8th, 2026 5:00 am
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms - Jun 2nd, 2026 6:00 am
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease - Apr 30th, 2026 5:00 am
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights - Apr 27th, 2026 6:00 am
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 - Apr 22nd, 2026 6:00 am